BRPI0913425A2 - formulações de niacina com liberação modificada - Google Patents

formulações de niacina com liberação modificada

Info

Publication number
BRPI0913425A2
BRPI0913425A2 BRPI0913425A BRPI0913425A BRPI0913425A2 BR PI0913425 A2 BRPI0913425 A2 BR PI0913425A2 BR PI0913425 A BRPI0913425 A BR PI0913425A BR PI0913425 A BRPI0913425 A BR PI0913425A BR PI0913425 A2 BRPI0913425 A2 BR PI0913425A2
Authority
BR
Brazil
Prior art keywords
modified release
release niacin
niacin formulations
formulations
modified
Prior art date
Application number
BRPI0913425A
Other languages
English (en)
Inventor
Dhanajay Singare
Harshal Prabhakar Bhagwatwar
Ish Kumar Khanna
Pradeep Jairao Karatgi
Rajesh Vooturi
Raviraj Sukumar Pillai
Shantanu Yeshwant Damle
Sesha Sai Marella
Original Assignee
Reddys Lab Ltd Dr
Reddys Lab Inc Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Reddys Lab Inc Dr filed Critical Reddys Lab Ltd Dr
Publication of BRPI0913425A2 publication Critical patent/BRPI0913425A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
BRPI0913425A 2008-06-02 2009-06-02 formulações de niacina com liberação modificada BRPI0913425A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1345CH2008 2008-06-02
US9416108P 2008-09-04 2008-09-04
IN1145CH2009 2009-05-18
PCT/US2009/045927 WO2009149058A2 (en) 2008-06-02 2009-06-02 Modified release niacin formulations

Publications (1)

Publication Number Publication Date
BRPI0913425A2 true BRPI0913425A2 (pt) 2015-11-24

Family

ID=41398815

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913425A BRPI0913425A2 (pt) 2008-06-02 2009-06-02 formulações de niacina com liberação modificada

Country Status (10)

Country Link
US (1) US20110123575A1 (pt)
EP (1) EP2296709A4 (pt)
JP (1) JP2011521977A (pt)
KR (1) KR20110011643A (pt)
CN (1) CN102105171A (pt)
AU (1) AU2009256394A1 (pt)
BR (1) BRPI0913425A2 (pt)
MX (1) MX2010013169A (pt)
TR (1) TR201009949T1 (pt)
WO (1) WO2009149058A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
DK2473045T3 (en) 2009-09-01 2016-12-12 Catabasis Pharmaceuticals Inc Niacin-FATTY ACID CONJUGATES AND THEIR USES
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
AU2012310251B2 (en) * 2011-09-16 2016-01-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
KR20150021071A (ko) * 2012-06-15 2015-02-27 코나리스 리써치 인스티튜트 아게 니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물
PT3079675T (pt) * 2013-12-13 2020-03-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
KR20160088436A (ko) 2013-12-13 2016-07-25 코나리스 리써치 인스티튜트 아게 니코틴아미드 및 5-아미노살리실산의 조합을 포함하는, 장내 세균총에 유익한 영향을 미치거나 및/또는 위장 염증을 치료하기 위한 약학 조성물
WO2020221574A1 (en) * 2019-04-30 2020-11-05 Dsm Ip Assets B.V. New delivery system for specific water-soluble vitamins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) * 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
EP1017390B1 (en) * 1997-07-31 2007-04-18 Kos Life Sciences, Inc. Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
ES2645930T3 (es) * 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
EP1684704A2 (en) * 2003-10-29 2006-08-02 Raif M. Tawakol Compositions and methods for increasing hdl and hdl-2b levels
MX2007012443A (es) * 2005-04-08 2007-12-13 Abbott Lab Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation

Also Published As

Publication number Publication date
JP2011521977A (ja) 2011-07-28
AU2009256394A1 (en) 2009-12-10
US20110123575A1 (en) 2011-05-26
EP2296709A4 (en) 2012-02-01
WO2009149058A2 (en) 2009-12-10
EP2296709A2 (en) 2011-03-23
TR201009949T1 (tr) 2011-03-21
WO2009149058A3 (en) 2010-02-25
WO2009149058A8 (en) 2010-07-15
CN102105171A (zh) 2011-06-22
MX2010013169A (es) 2010-12-21
KR20110011643A (ko) 2011-02-08

Similar Documents

Publication Publication Date Title
BRPI0914630A2 (pt) liberação dérmica
BRPI0907884A2 (pt) Partícula de liberação
BRPI0909220A2 (pt) Partícula de liberação
BRPI0818874A2 (pt) Liberação de agentes ativos
BRPI0916612A2 (pt) partícula de liberação
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
EP2381760A4 (en) CORN PROTEIN COMPOSITION
BRPI0922480A2 (pt) compósitos de nanocalcita
FIC20240018I1 (fi) Vamoroloni
BRPI0814188A2 (pt) Formulações
BRPI0917231A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0908114A2 (pt) tabuleta oral de liberação controlada
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
DK2278899T3 (da) Bryggemekanisme
BRPI0922728A2 (pt) combinação de herbicida-antídoto
BRPI0811732A2 (pt) Formulação de liberação prolongada de nevirapina
EP2296709A4 (en) NIACIN FORMULATIONS WITH MODIFIED RELEASE
EP2357204A4 (en) COMPOSITION

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired